StockNews.AI
FOLD
StockNews.AI
120 days

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

1. Amicus Therapeutics will discuss Q1 financial results on May 1, 2025. 2. Investors can access the call via phone or live audio webcast. 3. FOLD focuses on developing medicines for rare diseases. 4. The upcoming results may affect investor sentiment and stock price. 5. Archived materials will be available shortly after the live event.

3m saved
Insight
Article

FAQ

Why Bullish?

Company calls generally indicate businesses are progressing, potentially boosting investor confidence, similar to past quarterly calls where stocks rose post-announcement.

How important is it?

The earnings call is likely to provide critical updates about financial standings and future prospects, directly impacting investor perception and stock performance.

Why Short Term?

The upcoming financial report may cause immediate price fluctuations in response to earnings news, reflective of historical behavior around quarterly disclosures.

Related Companies

AMGNBIIBREGN
April 21, 2025 07:00 ET  | Source: Amicus Therapeutics, Inc. PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn. CONTACT: Investors:Amicus TherapeuticsAndrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com (609) 662-3809 Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Affairs and Communications dmoore@amicusrx.com (609) 662-5079 FOLD–G

Related News